Citations

Clear

2368 citation(s) found for "Su, Jack".

Lower Extremity Injuries and Revision Surgery Rates are Increased in Patients With Anorexia Nervosa and Bulimia Nervosa Compared With Controls
Woodrow, Jackson G. , Deckey, David G. , Lin, Eugenia, Haglin, Jack M. , Bingham, Joshua S. , Davies, Callie M. , Poon, Steven K. , Davies, Callie M , Poon, Steven K , Bingham, Joshua S , Lin, Eugenia , Patel, Karan A.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ars2.70057 | PMID 42724807 Get It

Purpose To compare lower extremity soft tissue injury and revision surgery rates for patients with anorexia nervosa (AN) and bulimia nervosa (BN) compared with matched controls. Methods This retrospective cohort study used a deidentified claims database. Patients were included if they carried an International Classification of Diseases code for AN or BN. Respective matched cohorts for AN and BN were created using propensity score matching. Primary and revision surgeries for anterior cruciate ligament (ACL) reconstruction, posterior cruciate ligament reconstruction, knee collateral ligament reconstruction, meniscus repair or meniscectomy, and any ankle ligament reconstruction were identified by their CPT codes. Patients over the age of 40 and without a minimum 2‐year follow‐up after primary surgery were excluded. Differences in prevalence and revision rates were analyzed. Results A total of 56,146 patients with AN and 42,630 patients with BN were included in this study with equal numbers in respective matched cohorts. Patients with BN showed an increased risk of ACL injury (relative risk = 1.32, P = .019), medial collateral ligament injury (1.17, 0.04), calcaneofibular sprain (1.92, <0.001), deltoid sprain (1.41, 0.004), and unspecified ankle sprain (1.44, <0.001). Patients with AN showed an increased risk for calcaneofibular sprain (1.25, 0.007), deltoid sprain (1.28, 0.015), and unspecified ankle sprain (1.17, <0.001). Patients with BN were more likely to have revision ACL repair (1.89, 0.02), partial meniscus revision (3.44, <0.001) and any meniscus revision (4.74, <0.001) while patients with AN were more likely to have an ACL revision (2.81, <0.001), partial meniscus (4.37, <0.001), and any meniscus (4.52, <0.001). Conclusions In this study, patients with AN and BN had a significantly increased risk for various knee and ankle injuries and revision surgeries compared with matched controls. Additionally, patients with AN and BN who sustained these injuries were more likely to undergo a revision surgical procedure within the first 5 years of the primary procedure. Level of Evidence Level III, retrospective comparative study.
TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Benatar, Michael, Lagier‐Tourenne, Clotilde , Gregory, Jenna, Al-Chalabi, Ammar, Boeve, Bradley F., Maragakis, Nicholas J., Wuu, Joanne, Zeier, Zane, Onyike, Chiadi, Lewcock, Joe, Hovinga, Collin, Jafar-nejad, Paymaan, Uspenskaya, Olga, Simmons, Adam, Browne, Susan E., Rohrer, Jonathan, Petrucelli, Leonard, Shapiro, Jacquelyn, Scharper, Deb, Boxer, Adam, Staffaroni, Adam M. , Dacks, Penny, Dave, Kuldip D. , Majo, Martina de, Mitic, Laura, Fradette, Stephanie , Haeberlein, Samantha Budd , Simuni, Tanya, Dunn, Billy, Lee, Edward B., Js, Gregory , Benatar, Michael, Barmada, Sami, Jicha, Gregory A. , Al‐Chalabi, Ammar , Boeve, Bradley F. , Jack, Clifford R. , Seeley, William W. , Maragakis, Nicholas J. , Wuu, Joanne , Zeier, Zane R. , Hovinga, Collin A. , Jafar‐Nejad, Paymaan , Uspenskaya, Olga, Simmons, Adam, Browne, Susan E. , Petrucelli, L, Ostrow, Lyle W. , Dacks, Penny A. , Turner, Martin R. , Majo, Martina de , Simuni, Tanya , McMillan, Corey T. , Lee, Edward B.

Mayo Clinic

JAMA Neurology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2812 | PMID 42636000 Get It

Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
Myocardial Inflammation and Necrosis in Juvenile Mice Compared with Adult Mice with Coxsackievirus B3 Myocarditis
Ricci, J.F. , Macomb, Logan P. , Gegoutchadze, Katherine, Davis, Charlotte, Ritter, Kyra G, Tomerlin, Priya, Darakjian, Ashley A. , Farahani, N A Sarbandi, Parrow, Lauren M, Strandes, Max W , Khatib, Sami , ElSaygh, Jude, Price, Jack F. , Gupta, Dipankar , Whelan, Emily R. , Tomerlin, Priya I, Beetler, Danielle J. , Florio, Damian N. Di , Cooper, Leslie T. , Fairweather, DeLisa , Bruno, Katelyn A.

Mayo Clinic

No container title available | August 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.746108 Get It

Background: Viral myocarditis presents a significant burden of disease, particularly among children and young adults. However, clinical guidelines and treatment strategies for pediatric patients are derived from those for adult patients due to a lack of pediatric data. Current animal models of viral myocarditis use adult mice, so conclusions from these models cannot necessarily be extrapolated to the pediatric population. We sought to develop a juvenile mouse model of myocarditis to examine differences between these two distinct clinical populations. Methods: Male and female BALB/c 3-4-week-old 'juvenile' and 8-week-old 'adult' mice were infected intraperitoneally with 103 PFU of heart-passaged coxsackievirus B3. Sera was used to evaluate testosterone and estradiol levels. Cardiac histological evaluations included overall inflammation, fibrosis, and specific cell-type infiltration. RNA was extracted from cardiac tissue and evaluated for changes in gene expression of cell-type markers, complement components, and NLRP3 inflammasome components. Results: Juvenile mice exhibited more severe inflammation than adult mice but no sex differences in overall inflammation. Juvenile mice demonstrated increased infiltration of CD11b+ cells, F4/80+ cells, and CD3+ T-cells vs. adults. Inflammasome genes NLRP3 and caspase-1 were significantly increased in juvenile compared with adult myocarditis. Conclusions: This paper is the first to describe a juvenile mouse model of coxsackievirus B3 myocarditis and provides a direct comparison to a translational adult mouse model. Juvenile mice had greater cardiac inflammation than adults. This model replicates clinical populations and provides a valuable tool to study age as a factor in the pathogenesis of myocarditis.
A Candid Appraisal of Repeat Blood Cultures in Candidemia—Missed Detection or Incident Infection?
Maamari, Julian , McHugh, Jack , Abu Saleh, Omar , Sohani, Zahra N

Mayo Clinic

Clinical Infectious Diseases | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag518 | PMID 42788983 Get It

Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants
Piura, Yoav , Aduen, Paula, Schecter, Leah, Jain, Manoj K, Algeciras‐Schimnich, Alicia, Petersen, Ronald C, Jr, Clifford R Jack, Graff‐Radford, Neill R, Lachner, Christian, Piura, Yoav D , Aduen, Paula A., Day, Gregory S , Jain, Manoj K, Algeciras‐Schimnich, Alicia , Figdore, Daniel J. , Bornhorst, Joshua , Petersen, Ronald C. , Jack, Clifford R. , Graff‐Radford, Neill R. , Lachner, Christian , Day, Gregory S.

Mayo Clinic

Alzheimer's & Dementia | August 20, 2026 | Volume: 22 | Issue: 8 | Pages: No page available

10.1002/alz.71763 | PMID 42619350 Get It

Abstract INTRODUCTION Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown. METHODS Cognitively normal Black, Hispanic, and non‐Hispanic White participants completed cognitive evaluations, brain magnetic resonance imaging (MRI), amyloid and tau positron emission tomography (PET), and measures of kidney function. Plasma p‐tau217 and Aβ42 were measured using Fujirebio Lumipulse assays. Pre‐clinical AD detection was evaluated using symptomatic and cohort‐derived optimized cutoffs. RESULTS Among 191 participants (57 Black, 46 Hispanic White, 88 non‐Hispanic White), age‐adjusted plasma p‐tau217 and p‐tau217/Aβ42 performed similarly in detecting amyloid‐positive individuals (≥ 25 Centiloids), regardless of race/ethnicity. Both measures independently correlated with amyloid deposition, whereas estimated glomerular filtration rate (eGFR) correlated solely with p‐tau217. Pre‐clinical AD optimized cutoffs (p‐tau217 ≥ 0.132 pg/ml; p‐tau217/Aβ42 ≥ 0.0059) outperformed cutoffs established in symptomatic individuals (sensitivity: 83% vs. 57%; 77% vs. 63%; negative predictive value [NPV] > 93%). DISCUSSION Plasma biomarkers performed similarly across ethnoracially diverse cohorts. Optimized cutoffs may improve early detection and trial enrollment.
Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A. , Ballman, Karla V. , Mercurio, Ann, Siegelin, Markus D., Tuohy, Kyle , Mansouri, Alireza , Simonelli, Matteo, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Hervey-Jumper, Shawn L., Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter, Neugut, Alfred I. , Iwamoto, Fabio M., Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Brown, Paul D , Vogelbaum, Michael A , Ballman, Karla , Mercurio, Ann , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Dehais, Caroline , Dipasquale, Angelo , Grinband, Jack , Yu, James B , Walch, Henry , Parker, Mitchell I , Shuryak, Igor , Roy, Soumyajit , Gallitto, Matthew , Horowitz, David P , McKhann, Guy M , Bruce, Jeffrey N , Ostrom, Quinn T , Neugut, Alfred I , Pike, Luke R G , Cheng, Simon K , Kachnic, Lisa A , Mehta, Minesh P , Wang, Tony J C , Minniti, Giuseppe , Siegelin, Markus D. , Kocakavuk, Emre , Ducray, François , Simonelli, Matteo , Yu, James B. , Hervey‐Jumper, Shawn L. , McKhann, Guy M. , Canoll, Peter , Ostrom, Quinn T. , Iwamoto, Fabio M., Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Journal of Clinical Oncology | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-01846 | PMID 42585601 Get It

PURPOSE Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era. METHODS The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database). RESULTS We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH -wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH -wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH -mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], P interaction < .001). In IDH -wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/–10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH -mutant glioma. CONCLUSION In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.
Immune Checkpoint Inhibitor–Associated Acute Kidney Injury
Fenoglio, Roberta , Murakami, Naoka , Sharon, Elad , Herrmann, Sandra M. , Workeneh, Biruh T., Roccatello, Dario, Blau, Jack A., Ostermann, Marlies , Ronco, Claudio , Renaghan, Amanda DeMauro , Rosner, Mitchell H. , Participants, on behalf of the ADQI Conference, Małyszko, Jolanta , Gupta, Shruti , Fenoglio, Roberta , Murakami, Naoka , Sharon, Elad , Herrmann, Sandra M , Ostermann, Marlies , Ronco, Claudio , Renaghan, Amanda DeMauro , Rosner, Mitchell H , Gupta, Shruti , Workeneh, Biruh , Roccatello, Dario , Leaf, David E.

Mayo Clinic

Journal of the American Society of Nephrology | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1681/asn.0000001232 | PMID 42536415 Get It

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with immune-related adverse events, including ICI–associated acute kidney injury (ICI-AKI). ICI-AKI presents diagnostic and management challenges and can influence decisions regarding immunosuppression and ICI rechallenge, with important implications for both kidney and cancer outcomes. An international, multidisciplinary panel convened at the 34th Acute Disease Quality Initiative (ADQI) consensus conference in September 2024. Systematic literature searches of PubMed were conducted to identify studies on the epidemiology, mechanisms, diagnosis, management, rechallenge, and outcomes of ICI-AKI. The meeting followed the established ADQI process and used a modified Delphi method to achieve consensus. Evidence was reviewed and appraised by workgroups, and consensus statements were developed through structured discussion and voting. Observational data suggest that AKI occurs in up to 20% of patients receiving ICIs, with ICI-AKI accounting for approximately 2%–5% of cases. Acute tubulointerstitial nephritis is the most common lesion, observed in 80%–90% of biopsies, although glomerular diseases are increasingly recognized. No clinical features reliably distinguish ICI-AKI from other causes of AKI, and kidney biopsy remains the diagnostic gold standard. Emerging urinary, circulating, and imaging biomarkers show promise but are not yet ready for routine clinical use. Early glucocorticoid initiation (within 3 days of ICI-AKI diagnosis versus >3 days after diagnosis) is associated with higher rates of kidney recovery, although optimal dosing and duration remain uncertain. Recurrent ICI-AKI occurs in fewer than 20% of patients undergoing ICI rechallenge. Management of high-risk populations, including kidney transplant recipients and patients with autoimmune disease or advanced CKD, requires individualized, multidisciplinary decision-making. ICI-AKI is an important and potentially reversible complication of cancer immunotherapy; these consensus statements provide a framework for diagnosis and management, support cautious ICI rechallenge in selected patients, and identify priorities for future research.